CLPT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLPT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net margin is calculated as Net Income divided by its Revenue. ClearPoint Neuro's Net Income for the three months ended in Sep. 2024 was $-4.97 Mil. ClearPoint Neuro's Revenue for the three months ended in Sep. 2024 was $8.12 Mil. Therefore, ClearPoint Neuro's net margin for the quarter that ended in Sep. 2024 was -61.24%.
The historical rank and industry rank for ClearPoint Neuro's Net Margin % or its related term are showing as below:
The historical data trend for ClearPoint Neuro's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClearPoint Neuro Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Net Margin % | Get a 7-Day Free Trial | -49.39 | -52.86 | -88.41 | -79.97 | -92.21 |
ClearPoint Neuro Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Net Margin % | Get a 7-Day Free Trial | -83.46 | -67.83 | -54.27 | -56.10 | -61.24 |
For the Medical Devices subindustry, ClearPoint Neuro's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's Net Margin % distribution charts can be found below:
* The bar in red indicates where ClearPoint Neuro's Net Margin % falls into.
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
ClearPoint Neuro's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as
Net Margin | = | Net Income (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | -22.089 | / | 23.955 | |
= | -92.21 % |
ClearPoint Neuro's Net Margin for the quarter that ended in Sep. 2024 is calculated as
Net Margin | = | Net Income (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | -4.974 | / | 8.122 | |
= | -61.24 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClearPoint Neuro (NAS:CLPT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of ClearPoint Neuro's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Lynnette C Fallon | director | 108 CHERRY HILL DRIVE, BEVERLY MA 01915 |
Linda M. Liau | director | 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075 |
Mazin Sabra | officer: Chief Operating Officer | 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075 |
Joseph Michael Burnett | director, officer: CEO and President | C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618 |
L. Jeremy Stigall | officer: GM, Biologics & Drug Delivery | 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075 |
Danilo D'alessandro | officer: Vice President, Finance | 5 MUSICK, IRVINE CA 92618 |
Harold A Hurwitz | officer: Chief Financial Officer | |
R John Fletcher | director | C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070 |
Girin Pascal E R | director | C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618 |
B Kristine Johnson | director | 366 FERNDALE RD S, WAYZATA MN 55391 |
Timothy T. Richards | director | ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103 |
Matthew B. Klein | director | C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
Marcio Souza | director | C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
Voyager Therapeutics, Inc. | 10 percent owner | 75 HAYDEN AVENUE, LEXINGTON MA 02421 |
Wendelin C Maners | officer: Vice President, Marketing | ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103 |
From GuruFocus
By GuruFocus Research • 05-08-2024
By Marketwired • 10-17-2024
By ACCESSWIRE • 11-08-2024
By GuruFocus News • 10-09-2024
By Marketwired • 08-07-2024
By GuruFocus Research • 05-08-2024
By GuruFocus News • 11-29-2024
By PRNewswire • 06-20-2024
By GuruFocus News • 10-23-2024
By GuruFocus News • 10-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.